ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Systematic Review
Revised

Post-stroke fatigue: a scoping review

[version 2; peer review: 2 approved]
PUBLISHED 25 Aug 2020
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Background: Post-stroke fatigue (PSF) is one of the most common and frustrating outcomes of stroke. It has a high prevalence and it can persist for many years after stroke. PSF itself contributes to a wider range of undesirable outcomes that affect all aspects of daily life. The aim of this review was to identify and summarise the most recent research on PSF, in order to update the evidence base.
Methods: We updated an existing review (Hinkle et al. 2017) systematically searching CINAHL, MEDLINE, PsycINFO, and PubMed to cover new research studies between 1st March 2016 and the search date (19th January 2020). We included interventional and observational research, and clinical practice guidelines that were not covered in the original review. After duplicate removal in EndNote, two reviewers screened the search results in Rayyan, and data from eligible full texts were extracted onto an Excel spreadsheet. Finally, we used RobotReviewer and a human reviewer to assess the risk of bias of randomised trials for this scoping review.
Results: We identified 45 records for 30 studies (14 observational, 10 interventional studies, and 6 guidelines). Apart from one, the interventional studies were single-centred, had high risk of bias and small sample size (median 50). They investigated exercise, pharmacotherapy, psychotherapy, education, and light therapy. Observational studies mainly reported the factors related to PSF including co-morbidities, depression and anxiety, quality of life, activities of daily living, stroke severity, medication use and polypharmacy, polymorphism, pain, apathy, limb heaviness, neuroticism, mobility, and thyroid-stimulating hormone. Guidelines either did not report on PSF or, when reported, their recommendations were supported by little or low level of evidence.
Conclusion: Although we identified a number of recent studies which have added to our current knowledge on PSF, none are robust enough to change current clinical practice.

Keywords

Post-Stroke Fatigue, Scoping Review

Revised Amendments from Version 1

In Table 2, we replaced the red and green colour keys with grey and white.
In Table 4, we added the effect sizes for interventional studies as reported in the original studies.
In the Discussion, we added the need for future research to include sensitivity analysis and the need for international standard reporting guidelines for measuring and reporting the outcomes. We suggested that future reviews should consider the impact of research on online delivery of interventions.
We changed `Limitations' to `Limitations and strengths' and added three key strengths of the current scoping review.
We changed 'Limitations' to 'Limitations and strengths' and added three strengths of the current scoping review.

See the authors' detailed response to the review by Carina U. Persson
See the authors' detailed response to the review by Nicola Hancock

Introduction

Post-stroke fatigue (PSF) has been defined as ‘overwhelming feeling of exhaustion or tiredness’, which is unrelated to exertion, and does not typically improve with rest1. It is one of the most common outcomes of stroke and its prevalence varies between 25% and 85%; however, it is generally accepted that it affects 50% of people after stroke2. PSF is linked to undesirable stroke outcomes and affects patients’ participation in studies, adherence to medication, and effectiveness of rehabilitation3. This has a negative impact on patients’ quality of life and daily life activities47, and also contributes to the burden on family members and carers8.

Although researchers have attempted to explain PSF mechanisms9, its aetiology still remains unclear. This is partly because there are many contributing factors to PSF8,1032, and each research team may focus only on some of the factors to find a route for preventing, treating or managing PSF. Any endeavour to find the most effective intervention in the research literature leads to a collection of heterogeneous interventions from physiotherapy33 and exercise3438 to psychotherapy, pharmacotherapy, and recently laser therapy3941.

As a systematic effort to review these scattered interventions, a Cochrane review42,43 compared all the tested PSF treatments to a control group, to standard care, or to each other, through reviewing randomised controlled trials (RCTs). This review concluded that there was insufficient evidence of the efficacy of the tested interventions in trials, and more robust research with adequate sample sizes was required42,43. Since then, more recent systematic reviews until 2019 have attempted to summarise the evidence of effectiveness of Modafinil, mindfulness training, a traditional Chinese medicine, and smart technologies, but still came to a similar conclusion to that of the Cochrane review in 20154447.

As a result of such uncertainty, current clinical practice guidelines rely on low levels of evidence, such as expert consensus, to make recommendations for PSF48,49. However, the efforts to design and test treatments continue, which makes it necessary to keep up-to-date with new research and practice literature.

Objective

The objective of this review was to identify and summarise the most recent research literature related to PSF in order to update the evidence base. As there was an existing review covering the literature up until 201650, we only updated the literature not covered in this review.

Methods

Methods from an existing review

In 2017, Hinkle et al.,50 published a review covering emerging evidence relating to the management of PSF, up to and including February 2016. Because of the comprehensiveness of this review, we only searched for literature published after 1st March 2016. As the search methods of the Hinkle et al., review were not reproducible, and the search strategies and results were not available, we contacted the corresponding author and their librarian on 15th October 2019. Since we did not receive a reply, we designed the search methods for the reported databases in order to capture the majority of the literature included in Hinkle et al.,’s review.

Scoping review methods

We followed Arksey and O’Malley framework51 for conducting this scoping review. We also used Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Extension for Scoping Reviews(PRISMA-ScR) for reporting52. The relevant PRSIMA-ScR checklist is available as Extended data and the flow diagram is reported in the Results section (Figure 1).

cc7ee73a-8c14-4bb3-becc-a1d070f154ec_figure1.gif

Figure 1. PRISMA flow diagram.

Search methods

We ran a search to include studies in the English language only, between 1st March 2016 and 19th January 2020 (search date) in CINAHL via EBSCOhost, MEDLINE via Ovid SP, PubMed (excluding MEDLINE), and PsycINFO via Ovid. There were no limitations to document type (e.g. thesis), study completion status (e.g. ongoing), and publication status (e.g. unpublished) at the search stage. We report the search strategies for all databases in Extended data.

Selection of studies

We imported the search results into EndNote X6 and de-duplicated them based on title, and additionally double-checked the automatically identified duplicates manually. Two reviewers (GA and FS) screened the results independently against the eligibility criteria using Rayyan, which is a recommended screening system53. Discrepancies were resolved through discussions or asking a third reviewer (AD).

Two reviewers (GA and FS) also investigated the full texts of relevant search results against the same criteria involving a third reviewer (AD) in case of disagreement. At full text screening stage, we also investigated the reference lists of the relevant studies to identify additional relevant studies. Since one study may have multiple reports or publications, we kept a record and cited all the reports of a single study to provide a better overview of the new research evidence.

Eligibility criteria

We included the following studies:

  • - Studies of adult humans with PSF – any definition of PSF – at any stage of the stroke care continuum;

  • - Any interventional (clinical trial) or observational (cohort, case-control, and cross-sectional) studies, and clinical practice guidelines;

  • - Studies reporting findings that had not been included in the previous review;

  • - Studies included in relevant systematic reviews.

We excluded the following studies:

  • - Studies with case reports, case series, and qualitative design;

  • - Studies included in Hinkle et al., or results which repeated the summarised knowledge in that review;

  • - Studies of pre-clinical nature;

  • - Clinical studies where fatigue was reported only as a side effect of the treatment;

  • - Studies focusing on single muscle fatigue or muscle fatigue in general;

  • - Studies not focusing on fatigue and/or stroke or focusing on heat stroke, athletes’ fatigue or carers’ fatigue;

  • - Systematic or narrative or review papers;

  • - Ongoing studies or protocols with no results (listed and cited in this paper for further follow-up);

  • - Tool validation studies without reporting new findings on PSF.

Data extraction methods

One reviewer (GA) extracted and entered the data in Excel 2007 and the second reviewer (FS) checked the extracted and entered data against the full text and, if appropriate, corrected or amended the data.

For interventional studies, we extracted PICOS (participants, intervention, comparison, outcomes, and study design) and other data points:

  • - Study name and year;

  • - Clinical trial registration number (for further check on selective reporting bias);

  • - Country of origin;

  • - Number of centres;

  • - Patients: Number of patients, type of stroke, time passed after stroke;

  • - Intervention and controls: name of intervention and duration;

  • - Primary and secondary outcomes measures in general and fatigue measures in particular, outcome endpoints, and main findings related to PSF;

  • - Study design (single-arm clinical trial (CT), controlled clinical trial (CCT), or RCT);

For observational studies, we extracted:

  • - Study name and year;

  • - Clinical trial registration number (for further check on selective reporting bias);

  • - Country of origin;

  • - Number of centres;

  • - Patients: Number of patients, type of stroke, time passed after stroke;

  • - Primary and secondary outcomes measures in general and fatigue measures in particular, outcome endpoints, and main findings related to PSF;

  • - Study design (cohort, case-control, or cross-sectional).

For clinical practice guidelines, we extracted the following data:

  • - Study name and year;

  • - Country and organisation who produced the guideline;

  • - Recommendations on PSF;

  • - Evidence base reporting the level of evidence or study designs related to the level of evidence.

Quality assessment methods

We used RobotReviewer for assessing the risk of bias in the four categories of the Cochrane Risk of Bias tool54 for included RCTs. Although this automation system is reliable for checking the risk of bias for certain bias categories55,56, one of the reviewers (GA) also double-checked and revised RobotReviewer’s assessment and corrected the data where necessary. We also added a ‘selective reporting of outcomes’ category to the list of biases to cover the main biases in Cochrane Risk of Bias tool. Because of ‘scoping’ nature of this review and lack of time and resources, we did not assess the risk of bias for non-RCTs.

Synthesis methods

We summarised the data from the new relevant literature in tables. We did not proceed to a meta-analysis for fatigue outcomes due to the heterogeneity of studies. We checked if any of the interventional studies considered following the CONSORT57 for reporting RCTs or TIDieR checklist58 to report the components of new interventions.

Results

The search identified 1021 results. After screening, we included 45 relevant records related to 24 studies and 6 guidelines (Figure 1).

The characteristics of included interventional studies have been charted in Table 1. The table shows eight RCTs some with multiple reports and one with a follow-up study5973, one CCT74, and two single-arm trials75,76. All studies were based on single centre studies, except for West et al., (2019) which had two centres71. In studies that reported the intervention delivery details, the psychological interventions were delivered individually and face-to-face – rather than online – by psychologists. We also assessed the risk of bias for RCTs and reported the categories of risk in Table 2 with supporting statements in Extended data.

Table 1. Characteristics of included interventional studies.

Study nameCountryDesignNo. of
participants
Stroke typeTime after
stroke
InterventionsDuration of interventionDelivered byDelivery
mode
Chen
et al., 2016
TaiwanRCT41With CHF64.95±53.07 DInspiratory Muscle
Training
+ TAU v. TAU
10 W (5 D/W)Respiratory
Therapist
NR
Chen
et al., 2019
TaiwanRCT72IschemicNRMind-Body Exercise
(Qigong) + TAU v. TAU
10 DResearchersIndividual
Delva 2019UkraineCCT39Ischemic/TIA≥3 MAcetylsalicylic Acid
(Low Dose v. High
Dose)
3 MNRNR
Liu et al., 2016TaiwanRCT64Haemorrhagic
/Infraction
≥3 MAstragalus
membranaceus
v. Placebo
28 DNRNR
Liu et al., 2018ChinaRCT140NRNRVitamin C v. Wuling12 WNRNR
MIDASAustraliaRCT36NR≥3 MModafinil v. Placebo6 WPatientsIndividual
Follow-
Up
18/36
Nguyen et al.,
2019
AustraliaRCT15//NRCBT v. TAU8 WPsychologists*Individual
Van Heest
et al., 2017
USA1-Arm
CT
49NRNRFatigue Management
Course
6 WClinical
Psychologist
Individual
West
et al., 2019
DenmarkRCT90NR7.6±8.3
(Treatment),
6.0±4.4
(Control) D
Naturalistic Lighting
(Artificial Sunlight
Spectrum) v. Standard
Indoor Lighting
45.3±22.1 (Treatment),
33.7±12.7 (Control) D
NAGroup
Wu et al., 2017UK1-Arm
CT
12First/Recurrent3±24 MManualised
Psychological
Intervention
7 SClinical
Psychologist
Individual

* Psychologists with doctoral qualifications in clinical neuropsychology.

RCT: Randomised Controlled Trial; CCT: CONTROLLED CLINICAL TRIAL; CT: Clinical Trial; NR: Not Reported; NA: Not Applicable; CHF: Congestive Heart Failure; TIA: Transient Ischaemic Attack; D: Day; W: Week; M: Month; S: Session

Table 2. Risk of bias assessed by RobotReviewer and a human reviewer for randomised controlled trials.

TrialRandom sequence
generation
Allocation
concealment
Blinding of
participants
and personnel
Blinding of
outcome
assessment
Selective
reporting of
outcomes
Chen et al., 2016???++
Chen et al., 2019++???
Delva 2019?????
Liu et al., 2016+++++
Liu et al., 2018?????
MIDAS+++++
Nguyen et al., 2019++?+?
West et al., 2019++??+

Question marks in grey cells indicate unclear or high risk of bias and plus signs in white cells show low risk of bias.

Most of the interventional studies have a medium to high risk of bias. Table 2 shows only two studies in white cells (indicating low risk of bias) but both have small sample size consisting of 34 (MIDAS study6368) and 64 randomised patients61 respectively.

We identified 14 observational studies of which half had a prospective cohort design7790 and the other half were cross-sectional surveys9197. Three cross-sectional surveys were embedded within cohort studies91,94,97. Only one of the studies (NotFAST) had a follow-up report8185. Details of all studies are reported in Table 3 as well as the Extended data.

Table 3. Characteristics of included observational studies.

Study nameCountryNo. of
centres
DesignNo. of
participants
Stroke typeTime after
stroke**
ARCOS-IVNew Zealand4Cross-Sectional
(in Cohort)
256/2096*First,Ischemic,Haemorrhagic,Undetermined4 Y
Blomgren et al.,
2019
Sweden1Cohort296/411First,Recurrent, Ischemic7 Y
Chen et al., 2018USA1Cohort128/203Ischemic, Haemorrhagic6 M
Choi-Kwon et al.,
2017a
South Korea1Cross-Sectional373/469Ischemic3 M
Choi-Kwon et al.,
2017b
South Korea1Cohort364/508Ischemic12 M
Douven et al.,
2017
Netherlands2Cohort243/250First, Ischemic3, 6, 12 M
Kuppuswamy
et al., 2016
UK3Cross-Sectional69First56.81±63 M
LAS-1Sweden1Cross-Sectional
(in Cohort)
349NR6 Y
Lau et al., 2017Hong Kong1Cross-Sectional191Ischemic3 M
MacIntosh et al.,
2017
Canada4Cross-Sectional335Ischemic, HaemorrhagicWithin 6 M
NotFASTUK4Cohort268/371First4-6 W
Follow-Up263/3716 M
STROKDEMFrance4Cohort153/179Ischemic, Haemorrhagic6 M
van Rijsbergen
et al., 2019
Netherlands1Cross-Sectional
(in Cohort)
208First, Ischemic, Haemorrhagic, Recurrent3.3±0.5 M
Wang et al., 2018China1Cohort634/703IschemicWithin 3 D

NR: Not Reported; Y: Year; M: Month; W: Week; D: Day

*For cohort studies, the left number shows the number of participants who finished follow-up, and the right number is the number of participants who started and took part in the study; for cross-sectional studies within cohort studies, the left number shows the number of participants in cross-sectional study and the right number is the number of participants in cohort study.

** Sometimes reported as time period and sometimes as mean and standard deviation across the studies.

Table 4 summarises the main finding of each interventional study all of which either have high risk of bias or small sample size. Such limitations make it hard to transfer the research findings to practice.

Table 4. Descriptive summary of findings from included interventional studies.

Study NameFatigue
measure
EndpointMain post-stroke fatigue finding*
Chen et al.,
2016
Secondary:
FAS
W 10There were no significant changes from baseline in FAS in either group (intervention:
p=0.218; control: p=0.475; change between groups: p=0.198).
Chen et al.,
2019
Fatigue VASD 5, 10Fatigue was not significantly associated with change in quality of life (β = −0.21,95% CI
[−0.73~;0.31],p=0.42) and was not different in two groups.
Delva, 2019FASD 3, M 1, 3The use of aspirin in high dose during 3 months with PSF diagnosis within the first days
post-stroke is associated with decreasing of fatigue intensity due to FAS and modifying
of post-stroke inflammatory response (р<0.05).
Liu et al.,
2016
Primary: BFID28±5,
84±5
Astragalus membranaceus group had improved fatigue in visit 1–28± 5 days – post-
therapy (p=0.01) and in follow-up in 84 ± 5 days post-therapy (p=0.05).
Liu et al.,
2018
Barthel IndexW 12Wuling can inhibit the release rate of inflammatory factor, reduce the expression level of
related inflammatory factors and improve PSF (p<0.05).
MIDASPrimary: MFIW 6, 7Modafinil group reported decrease in fatigue (β = −7.38, 95% CI [−21.76;
−2.99],p<0.001) and improvement in quality of life (β = 11.81, 95% CI [2.31; 21.31],
p=0.0148).
M 12MFI and quality of life at baseline and their changes during treatment were correlated (β
= −1.975, 95%CI [−3.082; −0.869], p < 0.001). Five of the patients who continued taking
daily modafinil demonstrated 33–38 point simprovement in MFI compared to baseline.
Nguyen et al.,
2019
Primary: FSSM 2, 4CBT group demonstrated reduced fatigue relative to TAU post-therapy (β = 1.74,95%CI
[0.70; 2.77],effect size (η2)=.52)and two months post-therapy (β =1.92, 95% CI [0.24;
3.60],effect size (η2)=.36).
Van Heest
et al.,
2017
Primary:
FACIT-
Fatigue
W 6, 12Participants showed reductions in fatigue at post-test (p<0.001; effect size (Cohen’s d)
= 21.19) and maintained it at follow-up (p=0.315; effect size (Cohen’s d) = 0.23).
West et al.,
2019
Primary: MFIDischargeAt discharge, patients from the naturalistic light group experienced less fatigue than the
indoor light group (diff = –20.6%, 95% CI [–35.0%; –3.0%],p = 0.025).
Wu et al.,
2017
Secondary:
FAS
S 6, 1, M 3Fatigue decreased post-treatment (mean difference=4.8, 95% CI [-2.1; 11.6], p = 0.15),
in one-month assessment (mean difference=7.0, 95% CI [-0.8; 14.8], p = 0.07), and in
three-month assessment (mean difference=9.3, 95% CI [1.4; 17.1]; p = 0.03).

FAS: Fatigue Assessment Scale; VAS: Visual Analogue Scale; BFI: Brief Fatigue Index; MFI: Multidimensional Fatigue Inventory; FSS: Fatigue Severity Scale; FACIT: Functional Assessment of Chronic Illness Therapy; W: Weeks; D: Day; M: Month; S: Session; TAU: Treatment As Usual; CBT: Cognitive Behavioural Therapy.

*Grey cells contain findings from low risk studies; however they have small sample size. We reported the data as reported in the original report.

The majority of observational studies investigated factors related to PSF including co-morbidities, physical and mental outcomes, illness characteristics, characteristics of interventions, and biomarkers (Table 5).

Table 5. Descriptive summary of findings from included observational studies.

Study nameFatigue
measure
Post-stroke fatigue finding
ARCOS-IVFSSHaving hypertension, diabetes mellitus, and arrhythmia at the time of stroke were associated
with increased PSF.
Blomgren et al.,
2019
FISFatigue was independently explanatory of worse outcome on FAI summary score and domestic
chores.
Chen et al., 2018FACIT-
Fatigue
Early PSF appears to be largely attributable to stroke severity, while chronic fatigue occurs
in the setting of medical co-morbidities and medication use.
Choi-Kwon et al.,
2017a
FSSOf the 6 polymorphisms examined, only one marker, that is, low-activity Monoamine Oxidase A
was associated with PSF in female patients.
Choi-Kwon et al.,
2017b
FSSMusculoskeletal pain and central post-stroke pain was related to fatigue.
Douven et al., 2017FSSNo association between apathy and fatigue was found at baseline and no interaction with time
was found. Change in fatigue from baseline to 12-month follow-up was associated with change
in depression and with change in apathy. Bidirectional associations were found between PSF
and PSD.
Kuppuswamy et al.,
2016
FSSThose with high perceived limb heaviness also reported significantly higher levels of fatigue
than those with no perceived limb heaviness, but there was no difference in weakness between
the 2 groups.
LAS-1FSSIn almost all Stroke Impact Scale domains the odds for PSF were higher in persons with a higher
perceived impact. Fatigue is still present in one-third of persons six years after stroke onset.
Lau et al., 2017FASFatigue severity positively correlated with NEO Five-Factor Inventory neuroticism scores.
MacIntosh et al.,
2017
FASFatigue and depressive symptoms are related distinctly to cognitive and mobility impairments
post-stroke. Fatigue was associated with poorer lower limb motor function, and with cognition
indirectly via depressive symptoms.
NotFASTFSS of FAIPre-stroke fatigue, having a spouse/partner, lower Rivermead Mobility Index score, and higher
scores on both the Brief Assessment Schedule Depression Cards and Beck Anxiety Index
were independently associated with PSF.Of those reporting fatigue initially 69% continued to
report fatigue in follow-up. New PSF cases were reported by 38%. Lower Nottingham Extended
Activities of Daily Living scores and higher Beck Anxiety Index scores were independently
associated with fatigue at six months.
STROKDEMCFSMedication use was not a PSF predictor; however, polypharmacy increased PSF severity.
van Rijsbergen et al.,
2019
FASFatigue was associated with CLCE scores, independent of demographic, cognitive
performance and stroke-related covariates. After including personality traits and coping
styles in the model, independent associations with CLCE scores were found for fatigue and
neuroticism.
Wang et al., 2018FSSThe serum levels of thyroid-stimulating hormone were inversely associated with the risk of PSF
in both the acute phase and at follow-up. Thyroid function profiles may be predictor of PSF after
acute ischemic stroke.

FSS: Fatigue Severity Scale; FIS: Fatigue Impact Scale; FACIT: Functional Assessment of Chronic Illness Therapy; FAS: Fatigue Assessment Scale; FAI: Fatigue Assessment Inventory; PSD: Post-Stroke Depression; CFS: Chalder Fatigue Scale; CLCE: Checklist for Cognitive and Emotional consequences following stroke

We identified six recent guidelines from three English-speaking countries including the UK49 and two North American countries (one from Canada48 and four from the USA98101). Among these, the Canadian guideline was the most recent and the only one with comprehensive recommendations on PSF. The UK guideline will be updated in 2021. Half of these guidelines, that is, all those from USA, have not provided specific recommendations on PSF, as reported in Table 6. In almost all the guidelines, the reliance on ‘experts’ consensus’ is apparent because of the limited evidence base for PSF (Table 6).

Table 6. Descriptive summary of included clinical practice guidelines.

CitationCountry-
Organisation
RecommendationEvidence base
Braun et al.,
2016
USA-AHA/ASANoneNR
Lanctot et al.,
2019
Canada-CSBPRSee pages 15–16 of guideline.RCT, CCT, CT,
Consensus
NICE 2017UK-NICEAssess the person for mental and physical factors that may contribute to fatigue.
Treat any reversible causes or exacerbating factors. Provide the person and their
family/carers with information and help in anticipating and managing fatigue such
as daily routines, modified tasks which balance activity and rest, planned exercise
schedules, and sleep hygiene.
Cochrane SR,
SR, Consensus
Peberdy et al.,
2017
USA-AHANoneNR
VA-DoD 2019USA-VA/DoDNoneNR
Winstein et al.,
2016
USA-AHA/ASAAn RCT compared a multi-component cognitive therapy + graded activity training
versus cognitive therapy for 12 weeks and showed that the multi-component
therapy is better than the cognitive therapy in reducing fatigue and improving
physical endurance … myths about exercise being unsafe, causing another
stroke, or increasingfatigueshould be dispelled during rehabilitation … evidence
is limited, many clinicians advise that for individuals who want to return to work, a
tailored assessment of cognitive, perception, physical, and motor abilities can be
performed to determine readiness and the needed accommodations to return
to work based on individual’s needs and capabilities for the specified job situation.
The assessment may include executive functions, high-level oral and written
communication, and fatigue. Once performance under the best conditions has
been assessed, further assessment under conditions of fatigue and stress may be
useful to mimic potential job situations.
RCT

AHA: American Heart Association; ASA: American Stroke Association; VA/DoD: Department of Veterans Affairs/Department of Defense; NICE: National Institute for Health and Care Excellence; CSBPR: Canadian Stroke Best Practice Recommendations by Management of Mood, Cognition and Fatigue Following Stroke Best Practice Writing Group/Heart & Stroke Canadian Stroke Best Practices and Quality Advisory Committee/Canadian Stroke Consortium; NR: Not Reported; RCT: Randomised Controlled Trial; CCT: Controlled Clinical Trial; CT: Clinical Trial; SR: Systematic Review.

Discussion

We conducted this review to identify and summarise the most recent research studies on PSF since Hinkle et al.,’s review (2017)50. We therefore documented the interventional and observational research and clinical practice guidelines since March 2016. However, there were some key contributors to the weak evidence base: (i) recording and reporting only some contributing factors to PSF in observational studies, (ii) the heterogeneity of designed interventions, (iii) high risk of bias, (iv) small sample size in interventional studies, and (v) variety of outcome measures in both observational and clinical studies. This, in turn, is reflected in the quality of the clinical recommendations for PSF.

Despite the high prevalence of PSF2 and its obvious effects on treatment adherence102, in practice, only half of recent stroke guidelines have clinical recommendations on PSF. Of those that do, two guidelines provide only brief recommendations, and only one provides comprehensive recommendations, but these are based on low levels of evidence48. The weak evidence base and the need to rely on expert consensus is likely to be the main reason that PSF is generally not covered in the guidelines.

The dominance of single-centred interventional studies with small sample sizes and interventions delivered within a 12-week period may be the reasons for absence of follow-up studies. MIDAS (interventional)6365 and NotFAST (observational)8185 are the only recent studies with novel and potentially long-term findings with larger sample size (in case of MIDAS 2)103 or with the intention to design an intervention (NotFAST2)104.

While the observational studies reported the type of stroke, the interventional studies did not include this important data, which makes it difficult to summarise studies. Most of participants entered the interventional studies three-months after stroke. This is likely to be due to a number of reasons; for example, fatigue is not recognised immediately after a stroke, some studies want to ensure that participants have a continuous fatigue, and there is competition for recruitment in the early stages to more acute trials. However, one issue worth considering is whether the construct of PSF holds for fatigue experienced in research participants recruited years after their stroke, and whether this fatigue is a function of other issues. Future systematic reviews could address this issue by conducting sensitivity analyses comparing studies that include participants many years after their stroke with those including participants immediately after their stroke.

The variety of the interventions tested in studies and trials underlines the complexity of PSF and is an indication to researchers that future interventions will probably need to target multiple aspects of fatigue. While current reporting practice of interventions in RCTs included in our review is of concern (none followed TIDieR and two followed CONSORT), future studies should consider following reporting guidelines such as CONSORT and TIDieR for interventional studies, STROBE for observational studies, and RIGHT105, AGREE106, or CheckUP107 for clinical practice guidelines. In addition, harmonisaton of studies requires standard international guidelines regarding outcome measurements and time points for measuring PSF in a standard way to create a homogenous and collective body of evidence.

Among the observational studies, the population-based study from the stroke register in New Zealand91 and Sweden77 provides valuable insights about the link between co-morbidities and increased PSF in long-term (4–7 years). This, and other similar register-based studies, represent the added value of having high-quality data in health system databases for long-term observational and register-based studies108.

Psychologists delivered the psychotherapies in RCTs to individual patients and there was no intervention using online platforms as the media of delivery. This may be due to a number of reasons: it is usual to test the efficacy of an intervention face to face before moving to another medium; participants with stroke may have other problems which mean it is more difficult to deliver treatments online, e.g. communication issue and cognitive problems. Online delivery of such interventions is becoming more common in some clinical services, and new research is emerging109. Therefore, future reviews may wish to consider the impact of such interventions delivered online.

Fatigue Severity Scale (FSS) was the main outcome measure for PSF in observational studies, whereas Fatigue Assessment Scale (FAS) was used more frequently than other measures in interventional studies. Bearing in mind that both these PSF measurement scales are valid and reliable, the main reason that the FSS has been used more frequently is probably because it is now seen as a way to compare different studies: in simple terms, researchers use it because other researchers have used it. It is also relatively straight forward to complete.

Only one of the observational studies and half of the interventional studies were registered in clinical trial registers, with the remaining unregistered trials potentially introducing bias in selective reporting of outcomes110,111. One of the interventional studies was registered retrospectively with potential for the same bias69,70.

Limitations and strengths

It is possible that we overlooked studies that did not report PSF in the searchable part of the paper or if the report was not indexed in the searched databases. In such cases, we invite readers of this review to contact us or comment on the paper online.

Due to the challenges we faced in identifying the search strategies in the previous review when conducting this update, we have explicitly documented our search criteria and strategies so that this review can be easily repeated and updated by future researchers. We feel this is a key strength of this review. We also feel that the use of automation tools such as Rayyan and RobotReviewer for this evidence synthesis was a strength in terms of saving time and other resources while still maintaining the quality of the review. Finally involving a multi-disciplinary team of clinicians and methodologists (information specialist and systematic reviewer) allowed us to consider both the clinical and methodological aspects of the studies in this review.

Conclusion

The current trend of research on PSF shows the continued importance of this topic globally. Our review identified a weak evidence base that highlights the need for more research that could have the following characteristics: I) studies to design and test multi-component interventions for PSF; and II) Robust RCTs with adequate sample sizes to produce the evidence for recommendations in guidelines. From our current knowledge on PSF, none of the recent studies are robust enough to change current clinical practice.

Data availability

Underlying data

Open Science Framework: Post-Stroke Fatigue: A Scoping Review, https://doi.org/10.17605/OSF.IO/XJKCS112.

Registration DOI: https://doi.org/10.17605/OSF.IO/XJKCS

This project contains the following underlying data:

  • - Extracted data from included studies

Extended data

Open Science Framework: Post-Stroke Fatigue: A Scoping Review, https://doi.org/10.17605/OSF.IO/XJKCS112.

This project contains the following extended data:

  • - Full search strategies

  • - Risk of bias assessment

Reporting guidelines

Open Science Framework: PRISMA-ScR checklist for ‘Post-stroke fatigue: a scoping review’, https://doi.org/10.17605/OSF.IO/XJKCS112.

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 07 Apr 2020
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Aali G, Drummond A, das Nair R and Shokraneh F. Post-stroke fatigue: a scoping review [version 2; peer review: 2 approved]. F1000Research 2020, 9:242 (https://doi.org/10.12688/f1000research.22880.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 2
VERSION 2
PUBLISHED 25 Aug 2020
Revised
Views
10
Cite
Reviewer Report 02 Sep 2020
Carina U. Persson, Department of Clinical Neuroscience, Rehabilitation Medicine, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 
Approved
VIEWS 10
The authors perfectly solved or clarified all the issues that I ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Persson CU. Reviewer Report For: Post-stroke fatigue: a scoping review [version 2; peer review: 2 approved]. F1000Research 2020, 9:242 (https://doi.org/10.5256/f1000research.27636.r70217)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 1
VERSION 1
PUBLISHED 07 Apr 2020
Views
22
Cite
Reviewer Report 04 May 2020
Nicola Hancock, School of Health Sciences, University of East Anglia, Norwich, UK 
Approved
VIEWS 22
Thank you for the invitation to review this interesting scoping review, focussing on an important area of current research highly relevant to multiple aspects of life after stroke- that of Post-Stroke Fatigue, PSF.

The current review updates ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Hancock N. Reviewer Report For: Post-stroke fatigue: a scoping review [version 2; peer review: 2 approved]. F1000Research 2020, 9:242 (https://doi.org/10.5256/f1000research.25259.r62109)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 25 Aug 2020
    Ghazaleh Aali, Institute of Mental Health, Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK
    25 Aug 2020
    Author Response
    We thank the expert reviewer for spending time on our review and for providing helpful comments. We have made amendments to the manuscript based on these comments.
     
    Comment: The ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 25 Aug 2020
    Ghazaleh Aali, Institute of Mental Health, Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK
    25 Aug 2020
    Author Response
    We thank the expert reviewer for spending time on our review and for providing helpful comments. We have made amendments to the manuscript based on these comments.
     
    Comment: The ... Continue reading
Views
37
Cite
Reviewer Report 22 Apr 2020
Carina U. Persson, Department of Clinical Neuroscience, Rehabilitation Medicine, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 
Approved with Reservations
VIEWS 37
I found this scoping review very exciting to read since it addresses a very important issue that needs to be managed daily in post-stroke rehabilitation. I believe that the interest in post-stroke fatigue is great from both researchers and clinically ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Persson CU. Reviewer Report For: Post-stroke fatigue: a scoping review [version 2; peer review: 2 approved]. F1000Research 2020, 9:242 (https://doi.org/10.5256/f1000research.25259.r62111)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 25 Aug 2020
    Ghazaleh Aali, Institute of Mental Health, Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK
    25 Aug 2020
    Author Response
    We are grateful to the expert reviewer for their interest in the topic and for spending time in reviewing this manuscript. We value their positive and thorough comments and have ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 25 Aug 2020
    Ghazaleh Aali, Institute of Mental Health, Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK
    25 Aug 2020
    Author Response
    We are grateful to the expert reviewer for their interest in the topic and for spending time in reviewing this manuscript. We value their positive and thorough comments and have ... Continue reading

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 07 Apr 2020
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.